Article
03 Jul 2026
Beyond The Boardroom: What The Star Entertainment Decision Means For Governance Leaders
AUTHORS CONTENT
Article
30 Mar 2026
When "non binding" isn't risk free: Heads of Agreement and preliminary documents
Article
31 Dec 2025
The Wrap: 2025 for ASX Boards & C-Suite
Article
15 Nov 2025
It's Still Advertising! Therapeutic Goods And Social Media
Article
24 Aug 2025
Charting A Strategic Path To AGM Success
Article
22 Jun 2025
Time to brush up on continuous disclosure obligations – ASX to introduce a "close review procedure"
Article
03 Jun 2025
Schemes of Arrangement – What not to do as a substantial shareholder. Unacceptable circumstances
Article
15 Mar 2025
To name or not to name? ASX revises its approach to continuous disclosure obligations for market sensitive contracts
Article
02 Nov 2024
Webinar Q&As: Navigating the New Australian Anti-Bribery Laws | What You Need to Know
Article
30 Oct 2024
Webinar Q&As: 2024 ‘Clause & Effect' Series | Navigating contractual risks: Limitation of liability, warranties, and consequential losses
Article
22 Aug 2024
Corporate takeovers done lawfully: A guide for unlisted public companies in growth mode
Article
31 Aug 2023
Making the most of your AGM and Annual Report
Article
16 Dec 2022
Protected: Webinar Q&As: Crisis Management – When it hits the fan… responding to a crisis
Article
05 Oct 2022
Continuous disclosure for life sciences companies
Article
14 Sep 2022
Setting course for an effective AGM
Article
02 Aug 2022
What does good governance look like?
Article
25 Apr 2022
Bidding battle for Virtus – Takeovers Panel weighs in
Article
24 Jan 2022
Therapeutic Goods Advertising Code 2021: a simplified approach
Article
04 Oct 2021
COVID-19 testing at home: new regulation to allow rapid antigen self-tests
Article
31 Aug 2021
COVID-19 rapid antigen tests: complying with advertising and supply requirements